Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Subunit Plague Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 18-55months old as established by medical history and clinical examination.~* The subjects' guardians are able to understand and sign the informed consent.~* Subjects who can and will comply with the requirements of the protocol.~* Subjects with temperature ≤37.0°C on axillary setting.~Exclusion Criteria:~* Family history of seizures or progressive neurological disease.~* Subject who has a medical history of plague, or had been vaccination of plague vaccine.~* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine.~* Any confirmed or suspected autoimmune diseases or immune deficiency disorders, including human immunodeficiency virus (HIV) infection.~* Dysgenopathy or severe chronic disease.~* Pregnant or lactating women.~* Women of reproductive age without contraception.~* Thrombocytopenia or other blood coagulation disorder, may cause taboo of intramuscular injection.~* Any prior administration of immunodepressant or corticosteroids, and antianaphylactic treatment, cytotoxic therapy in last 6 months.~* Difficult to collecting blood sample.~* Any prior administration of blood products in last 3 month.~* Any prior administration of other research medicines in last 1 month.~* Any prior administration of attenuated live vaccine in last 4 weeks.~* Any prior administration of subunit or inactivated vaccines in last 2 weeks.~* Had fever before vaccination, subjects with temperature \>37.0°C on axillary setting.~* Rash on the injection site that may affect safety observation.~* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives.~Exclusion Criteria for the second dose:~* Subject who must be excluded according to the exclusion criteria for the first dose.~* Any serious adverse events caused by vaccination.~* Hypersensitivity after vaccination (include urticarial or rash in 30 minutes after vaccination).Hypersensitivity after vaccination (include urticarial or rash in 30 minutes after vaccination).~* Other adverse reactions in the opinion of the investigator that affect continue vaccination (include: severely serious symptom of pain, swelling, Limitation of motion, continuous high fever, headache and other Systemic or local reactions).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 15µg vaccine (Type: EXPERIMENTAL): 15µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
- 30µg vaccine (Type: EXPERIMENTAL): 30µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).